Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
PDZ1 Domain inhibitor peptideCat. No. 2207 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
Biological Activity
Novel cyclic peptide that disrupts interaction between GluR6 and the postsynaptic density protein 95 (PSD-95). Competes with the C-terminus of GluR6 for binding to the PDZ1 domain of PSD-95. Inhibits clustering of kainate receptors.Technical Data
M.Wt:(Modifications: Ala-6 = β-Ala, Cyclized = Lys-3 - Ala-6))
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Piserchio et al (2004) Targeting specific PDZ domains of PSD-95: structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. Chem.Biol. 11 469. PMID: 15123241.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: PDZ1 Domain inhibitor peptide, supplier, Disrupts, interaction, between, GluR6, PSD-95, PDZ1, domain, Glutamate, Kainate, Receptors, iGluR, Ionotropic
Quick Order
Find multiple products by catalog number
Pain Research Product Guide
Highlights over 280 products for Pain research. Request copy or view PDF today.
Calcium Imbalance and Neuroprotective Targets
Written by E. Besancon et al
'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
New Products in this Area
NR2B-selective NMDA receptor antagonist
PF 4778574Positive allosteric modulator of AMPA
CMPDAPositive allosteric modulator of GluA2 receptors
Tocris Events
Win a Kindle
Federation of European Biochemical Societies Congress 2013
July 6 - 11, 2013
St. Petersburg, Russia
Booth Number: 128